2014-06-17 20:07:56 UTC

Therapeutic Treatment for Celiac Disease Proves Effective in Phase 2 Trial

June 19, 2014

Marja-Leena Lähdeaho and colleagues report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease, necessitating strict life-long exclusion of dietary gluten. Despite adherence to a gluten-free diet, many patients remain symptomatic and still have small intestinal inflammation. In this case, nondietary therapies are needed. Marja-Leena Lähdeaho and colleagues investigated the ability of ALV003, a mixture of two recombinant gluten-specific proteases given orally, to protect patients with celiac disease from gluten-induced mucosal injury in a phase II trial. They report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gastroenterology 2014: 146(7): 1649-1658

More on Celiac Disease

The Lowdown on the Low-FODMAP Diet

Nov. 1, 2017

As the low-FODMAP diet grows in popularity, know the facts to help answer patient questions and provide guidance.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Avoidance of Cow's Milk–Based Formula for At-Risk Infants Does Not Reduce Development of Celiac Disease: A Randomized Controlled Trial

Oct. 1, 2017

Increased cow's milk antibody titers before the appearance of anti-TG2A and celiac disease indicates that subjects with celiac disease might have increased intestinal permeability in early life.